Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

Inclusion Criteria

• •Arm 1:
• •Age range: 50 ≤ age \< 90.
• •Diagnosis of dementia with Lewy bodies (DLB), Parkinson disease dementia (PDD), Parkinson disease with Mild Cognitive Impairment (PD-MCI), Mild Cognitive Impairment with Lewy bodies (MCI-LB).
• •DLB participants must fulfill criteria for clinically probable DLB based on the 2017 4th consensus report of the DLB consortium.
• •PDD participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and must also meet criteria for probable PDD based on the 2007 Movement Disorders Society clinical diagnostic criteria.
• •PD-MCI participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and meet criteria for Mild Cognitive Impairment on cognitive testing at screening.
• •MCI-LB participants with must meet established research criteria.
• •Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.
• •Availability of informant (for participants meeting criteria for dementia).
• •Ability and willingness to comply with the study-related procedures.
• •Fluent in spoken and written English (due to cognitive testing)
• •Completed Aim 1.
• •Clinical diagnosis of LBD (DLB or PDD) with CF.
• •Not taking a cholinesterase inhibitor and has not taken a cholinesterase inhibitor in the previous 90 days.
• •Ability and willingness to comply with the ChEI Cohort procedures (including galantamine administration), or a caregiver willing and able to ensure compliance.
• •Arm 3 (Healthy Controls)
• •Age range: 50 ≤ age \< 90.
• •Healthy controls should not have any known neurologic conditions that could interfere with study procedures or results.
• •Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.
• •Availability of informant (for participants meeting criteria for dementia).
• •Ability and willingness to comply with the study-related procedures.
• •Fluent in spoken and written English (due to cognitive testing).